Biopharma thought leadership

Removing bottlenecks in downstream processing purification

In the production of monoclonal antibodies (mAbs), finding ways to remove bottlenecks and improve yields in downstream processing continues to be a key focus area for biopharma manufacturers.

Bioprocessing in a Post-COVID-19 World

COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants

Charting the Rise of Single Use

Single-use systems have come a long way. Timothy Korwan and Sean DeFusco, single-use experts from Avantor, discuss biopharma’s experience with the technology so far – and consider why it has become a popular choice for producing new drugs.

Alternative buffer management strategies to achieve downstream process improvements

There has been significant change across the biomanufacturing industry over the last couple of decades, as increased complexity of biologics and a growing focus on smaller patient populations have led to a greater need for cost control and process efficiency.

Vaccine manufacturing: COVID-19 and beyond

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

Single-use technology in cell and gene therapies

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

Improving mAb Manufacturing Productivity

It is common for biologics manufacturing processes to require hundreds of raw materials, ranging from media and media supplements, buffers, and salts to other process chemicals...

Advancing gene therapy scale-up challenges

As the biopharmaceutical industry sharpens its focus on gene therapy, opportunities for advancements and challenges in manufacturing processes still remain. Dr. Ger Brophy, executive vice president of biopharma production at Avantor, offers insights on how the biopharma industry can evolve its processes through lessons learned from manufacturing monoclonal antibodies (mAbs) or vaccines, improving supplier collaboration, and other factors.

Addressing Key Challenges Optimizing Downstream Bioprocessing

The term “optimize” is often applied to complex manufacturing, automation and business processes and implies that the most efficient function of all the elements of a process – technologies, sequences and procedures – has not been achieved...

Managing Single Use Supply Chain

With the rapid growth of single-use systems (SUS) for drug production, especially by drug manufacturers with multiple locations across the globe, there are many risks associated with underestimating the regulatory compliance, manufacturing and quality requirements of these systems...

Optimizing Upstream Bioprocessing

Despite significant advances made in recent years to increase biologic yields as well as the intensity and consistency of these processes, there is still the potential for innovation in this area in order to reach more efficient production of therapeutic proteins...

Considerations in Controlling Glycosylation

Continued expansion of the biosimilar marketplace has led to many commercial opportunities and technical challenges...

Challenges in Chromatography

Processing times can be reduced and yields increased by utilizing new hydrophobic interaction chromatography tools.

Opportunities and challenges in cell and gene therapy development

Q&A interview with Ger Brophy, Executive Vice President for Biopharma Production at Avantor.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.